Expanding our non-CYP inhibition service portfolio
26 February 2015
To further expand our highly esteemed metabolism service portfolio, we are pleased to announce the launch of non-CYP inhibition services. These assays are a solid addition to our non-CYP metabolism and reaction phenotyping services, strengthening our goal to offer a complete range of metabolism assays for customers.
The new and validated non-CYP inhibition assays were developed for flavin mono-oxygenases (FMO1/FMO3), monoamine oxidases (MAO A/MAO B) and N-acetyltransferases (NAT1/NAT2). Furthermore we have earlier established inhibition assays for various glucuronosyltransferase (UGT) enzymes; UGT1A1, UGT1A4, UGT1A6, UGT1A9, UGT2B7 and UGT2B15. All the assays are available using recombinant enzymes with specific substrates and LC/MS-MS endpoint, delivering IC50.